Navigation Links
Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0%
Date:7/24/2014

DUBLIN, July 24, 2014 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received an AB therapeutic equivalent rating from the U.S. Food and Drug Administration (FDA) for its previously approved New Drug Application (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo's testosterone product is therapeutically equivalent to [AbbVie's] AndroGel 1% and can be substituted with the full expectation that it will produce the same clinical effect and safety profile as AndroGel 1% when used under the conditions specified in the labeling. Other companies that have submitted NDAs referencing AndroGel® 1.0% have failed to achieve the AB rating.

Androgel® 1.0% (testosterone gel 1.0%) is indicated to treat adult males who have low or no testosterone. Annual sales were greater than $500 million, as measured by Symphony Health Solutions.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "We are very pleased to receive an AB rating for our testosterone 1.0% product. It occurred as a result of a strong effort by our research and development team, which worked alongside the FDA. We sincerely commend the FDA team on its actions and appreciate their hard work to bring this matter to conclusion. This highlights our commitment to bringing new affordable products to the market."

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri®. The Company is the world's largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo's mission is to offer uncompromised "Quality Affordable Healthcare Products®" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2013, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Photo - http://photos.prnewswire.com/prnh/20120301/DE62255LOGO


'/>"/>
SOURCE Perrigo Company
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company plc To Host Investor Day And To Present At The 32nd Annual J.P. Morgan Healthcare Conference
2. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
3. Perrigo Confirms Filing For Generic Version Of Acanya
4. Perrigo Shareholders Approve Proposals Related To Perrigos Proposed Acquisition Of Elan
5. Perrigo Company Announces Tender Offer and Consent Solicitation for its 2.950% Notes due 2023
6. Perrigo Initiates Nationwide Voluntary Product Recall Of Acetaminophen Infant Suspension Liquid, 160 mg/5 mL, Due To A Potential Defect With The Co-Packaged Oral Syringe
7. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
8. Perrigo Company To Release First Quarter Fiscal Year 2014 Results On October 31, 2013
9. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue and Earnings
10. Perrigo Nutritionals Works with the American Academy of Pediatrics (AAP) on Infant Nutrition Educational Initiative
11. Perrigo Company Will Release Fourth Quarter And Fiscal Year 2013 Results On August 15, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine ... to reach $724 million by 2022, growing at a CAGR of 3.6% during ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 /PRNewswire/ ...  a leading organization within medical affairs in the ... as the chair of a newly formed ... additional board members to form the first ever ... For more information about the ACMA, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
(Date:3/27/2017)... ... 2017 , ... ?Grow Healthy Vending LLC announced today that ... itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ United States ... that we have now reached a settlement agreement regarding the ongoing lawsuits between ...
(Date:3/27/2017)... ... 27, 2017 , ... The homeowner improvement and repair market is expected to ... unlicensed contractors for renovations is also on the rise. Per a 2017 report, 13% ... those, 42% failed to use a licensed contractor.(2) The risks associated with improper renovations—especially ...
(Date:3/25/2017)... Square, PA (PRWEB) , ... March 25, 2017 , ... ... priority as a public relations partner. , All through the year, Garden Media ... and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... at the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships ... world’s premier prehospital trauma education developed in cooperation with the American College of ...
Breaking Medicine News(10 mins):